{"schema_version":"secwatch.filing_event.v1","accession":"0001062822-26-000112","form_type":"8-K","ticker":"LXRX","cik":"0001062822","company_name":"LEXICON PHARMACEUTICALS, INC.","filed_at":"2026-08-06T11:33:24+00:00","discovered_at":"2026-08-06T11:35:00.319643+00:00","generated_at":"2026-08-06T11:35:09.277017+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Lexicon Q2 net loss $31.8M; SONATA-HCM enrollment complete; ZYNQUISTA NDA resubmission Q4 2026","bullets":["Net loss $31.8M ($0.07/share) vs net income $3.3M ($0.01/share) in Q2 2025; total revenue $0.7M (all INPEFA) vs $28.9M (incl $27.6M licensing) YoY.","Cash and investments $190.6M at June 30, 2026, up from $125.2M at Dec 31, 2025; $100M Hercules loan facility entered, $55M drawn.","SONATA-HCM Phase 3 enrollment completed (exceeded 500 patients); top-line data expected Q1 2027.","ZYNQUISTA NDA resubmission for T1D expected Q4 2026, pending STENO1 safety data.","LX9851 Phase 1 by Novo Nordisk ongoing; Lexicon eligible for up to $1B milestones plus royalties."],"urls":{"canonical":"https://secwatch.observer/filing/0001062822-26-000112","json":"https://secwatch.observer/filing/0001062822-26-000112.json","markdown":"https://secwatch.observer/filing/0001062822-26-000112.md","text":"https://secwatch.observer/filing/0001062822-26-000112.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000112/0001062822-26-000112-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000112/lxrx-20260806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-06T11:35:09.277017+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}